ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,283.40
      0.11%
      US Tech 100
      18,126.80
      0.55%
      Dow Jones
      38,571.03
      -0.30%
      Brent Oil
      78.14
      -3.30%
      Bitcoin
      68,927.49
      1.74%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Milestone Pharmaceuticals Inc (MIST)

      7. Milestone Pharmaceuticals Inc (MIST) News

      MIST

      Milestone Pharmaceuticals (MIST)

      Milestone Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:MIST
      DateTimeSourceHeadlineSymbolCompany
      05/29/20247:09AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MISTMilestone Pharmaceuticals Inc
      05/22/20248:00AMGlobeNewswire Inc.Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT AwarenessNASDAQ:MISTMilestone Pharmaceuticals Inc
      05/13/20247:34AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MISTMilestone Pharmaceuticals Inc
      05/13/20246:59AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MISTMilestone Pharmaceuticals Inc
      03/04/20249:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MISTMilestone Pharmaceuticals Inc
      03/01/20244:52PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MISTMilestone Pharmaceuticals Inc
      02/29/20247:00AMGlobeNewswire Inc.Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded WarrantsNASDAQ:MISTMilestone Pharmaceuticals Inc
      02/28/20244:37PMGlobeNewswire Inc.Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded WarrantsNASDAQ:MISTMilestone Pharmaceuticals Inc
      02/26/20247:06AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MISTMilestone Pharmaceuticals Inc
      02/14/20248:56PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MISTMilestone Pharmaceuticals Inc
      02/14/20247:10AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MISTMilestone Pharmaceuticals Inc
      12/26/20238:54AMDow Jones NewsMilestone Pharmaceuticals Shares Sink 24% After Receiving Rejection from FDANASDAQ:MISTMilestone Pharmaceuticals Inc
      12/26/20237:57AMDow Jones NewsMilestone Pharmaceuticals' Etripamil Nasal Spray Application Gets FDA's Refusal to File LetterNASDAQ:MISTMilestone Pharmaceuticals Inc
      12/26/20237:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MISTMilestone Pharmaceuticals Inc
      11/21/20237:00AMPR Newswire (Canada)Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare ConferenceNASDAQ:MISTMilestone Pharmaceuticals Inc
      11/21/20237:00AMPR Newswire (US)Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare ConferenceNASDAQ:MISTMilestone Pharmaceuticals Inc
      11/13/20237:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MISTMilestone Pharmaceuticals Inc
      11/13/20236:57AMPR Newswire (Canada)Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate UpdatesNASDAQ:MISTMilestone Pharmaceuticals Inc
      11/13/20236:57AMPR Newswire (US)Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate UpdatesNASDAQ:MISTMilestone Pharmaceuticals Inc
      11/13/20236:37AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MISTMilestone Pharmaceuticals Inc
      11/13/20236:09AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MISTMilestone Pharmaceuticals Inc
      11/11/202310:00AMPR Newswire (US)Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023NASDAQ:MISTMilestone Pharmaceuticals Inc
      11/11/202310:00AMPR Newswire (Canada)Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023NASDAQ:MISTMilestone Pharmaceuticals Inc
      11/09/20234:43PMEdgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:MISTMilestone Pharmaceuticals Inc
      11/07/20239:07AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MISTMilestone Pharmaceuticals Inc
      11/07/20237:00AMPR Newswire (US)Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVRNASDAQ:MISTMilestone Pharmaceuticals Inc
      11/07/20237:00AMPR Newswire (Canada)Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVRNASDAQ:MISTMilestone Pharmaceuticals Inc
      10/24/20234:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MISTMilestone Pharmaceuticals Inc
      10/24/20237:00AMPR Newswire (US)Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for EtripamilNASDAQ:MISTMilestone Pharmaceuticals Inc
      10/24/20237:00AMPR Newswire (Canada)Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for EtripamilNASDAQ:MISTMilestone Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:MIST

      Your Recent History

      LSE
      TF62
      Magyar 27 S
      Delayed Upgrade Clock